Donoghue Forlines’s Idexx Laboratories IDXX Stock Holding History

Donoghue Forlines’s Portfolio IDXX Stock Details IDXX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-2,746	Closed	-$1.48M	–	243
2024 Q1	$1.48M	Sell	2,746 -116	-4%	-$63.4K	0.42%	74
2023 Q4	$1.59M	Buy	2,862 +269	+10%	+$126K	0.5%	43
2023 Q3	$1.13M	Sell	2,593 -5	-0.2%	-$2.49K	0.4%	83
2023 Q2	$1.3M	Buy	+2,598	New	+$1.24M	0.41%	57
2022 Q1	–	Sell	-2,945	Closed	-$1.94M	–	281
2021 Q4	$1.94M	Buy	2,945 +152	+5%	+$95.4K	0.33%	55
2021 Q3	$1.74M	Sell	2,793 -416	-13%	-$280K	0.34%	69
2021 Q2	$2.03M	Sell	3,209 -217	-6%	-$120K	0.38%	57
2021 Q1	$1.68M	Buy	+3,426	New	+$1.72M	0.33%	78
2019 Q3	–	Sell	-9,580	Closed	-$2.64M	–	171
2019 Q2	$2.64M	Buy	+9,580	New	+$2.36M	0.31%	80
2018 Q2	–	Sell	-12,864	Closed	-$2.46M	–	166
2018 Q1	$2.46M	Buy	+12,864	New	+$2.37M	0.21%	78

Other funds holding IDXX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Fundsmith LLP London, United Kingdom $12.8B AUM 6.9% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BAMCO Inc New York $33.1B AUM 11.16% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Donoghue Forlines's IDXX Position: Q2 2024 in Review

Donoghue Forlines sold out of Idexx Laboratories (IDXX) in Q2 2024, closing a stake of 2,746 shares — an estimated $1.48M sold.

Donoghue Forlines first reported a position in IDXX in Q1 2018 and held it in 10 quarters. The position peaked at $2.64M in Q2 2019. 1,109 funds tracked by Wall St. Rank hold IDXX as of Q2 2024.

Donoghue Forlines reported no remaining Idexx Laboratories position as of Q2 2024 after selling out during the quarter.
Donoghue Forlines sold 2,746 Idexx Laboratories shares in Q2 2024, an estimated $1.48M.
Donoghue Forlines first reported a position in Idexx Laboratories in Q1 2018 and held it in 10 quarters.
Donoghue Forlines's Idexx Laboratories position peaked at $2.64M in Q2 2019.
1,109 funds tracked by Wall St. Rank held Idexx Laboratories as of Q2 2024.

Based on Donoghue Forlines's 13F filing for Q2 2024, filed 6 Aug 2024.